News
Seminar

Shensi Shen, PhD

Singapore-Sichuan Frontier Medical Center, West China Hospital,

Institute of Thoracic Oncology, Chengdu, China

"The 50 shades of drug-tolerant persister cells in cancer"

host: A. David (IRCM)

Frederic BOST & Nathalie MAZURE

Equipe "Cancer, Metabolism & Environment"

Inserm U1065/ Université Côte d'Azur (Nice)

Centre Méditerranéen de Médecine Moléculaire (C3M)

"Cross-Perspectives on Prostate Cancer: Metabolism and Primary Cilium"

host: Eric JULIEN (IRCM)

 Michel COHEN-TANNOUDJI

Institut Pasteur (Paris)

"When Retrotransposons and Immune Ribonucleases Shape Speciation: The Case of The Maternal Hybrid Incompatibility of the Mouse DDK Strain"

hosts: Alexandre David & Laurent Le Cam (IRCM)

Luca GRUMOLATO

ROUEN University, INSERM U982

"Tracking cell heterogeneity to investigate lung cancer acquired resistance to EGFR-TKIs"

host : A. Maraver (IRCM)

Sylvain Delaunay

Cancer research UK (CRUK) Manchester Institute

"Unravelling metastatic processes: the power of RNA modifications"

host : L. Le CAM (IRCM) 

 Bhumi Bhatt, PhD

Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta

"Molecular subtypes of human skeletal muscle in cancer cachexia"

host : Alexandre Djiane (IRCM)

Prof. Resia PRETORIUS

Physiological Sciences Department, Faculty of Science, Stellenbosch University, South Africa.

"Where Clotting Meets Immunity: Uncovering Novel Drivers of Chronic Illnesses"

Resia Pretorius is a Distinguished Professor at Stellenbosch University (South Africa), Honorary Professor at the University of Liverpool, and founding director of Biocode Technologies. Her research focuses on how inflammation disrupts coagulation and  immune function, leading to microclots, platelet activation, and endothelial pathology across diseases including cancer, diabetes, cardiovascular disease and Long COVID. She has published over 330 papers, filed multiple patents on microclot diagnostics, and serves on global health advisory panels including the WHO.

host : Alain R. Thierry (IRCM)

Rob NOBLE, PhD

Senior Lecturer, 

City St George's, University of London

"Using mathematical modelling to support trials of evolutionary cancer treatment strategies"

host : (N. Bonnefoy, IRCM)

selected publications :

Bacevic K*, Noble R*, Soffar A, Ammar OW, Boszonyik B, Prieto S, Vincent C, Hochberg ME, Krasinska L, Fisher D. Spatial competition constrains resistance to targeted cancer therapy. Nature Communications (2017) 8, 1995

Viossat Y, Noble R. A theoretical analysis of tumour containment. Nature Ecology & Evolution (2021)

Patil S, Viossat Y, Noble R. Preventing evolutionary rescue in cancer. bioRxiv (2023)

FRANCOIS FUKS

Université Libre de Bruxelles

"Cancer Epigenetics : from New Mechanisms to New Therapies"

host : Laurent Le Cam (IRCM)

Professor Generoso BEVILACQUA

https://orcid.org/0000-0001-8857-2609

Department of Translational Research and New Technologies in Medicine, University of Pisa, Italy.

"Viral Origin of Breast Cancer"

hôte : Andrei TURTOI (IRCM)

Professor Kazuya KABAYAMA

Institute for Radiation Sciences, Osaka University, Japan

"Alpha-targeted therapy by regulating the intracellular dynamics of antibody drugs"

Professor Kazuya Kabayama leads the Laboratory for Radiation Chemical Biology at Osaka University, where his research bridges chemistry, cellular biology, and nuclear medicine. His primary focus is on developing innovative treatments in radiotherapy, particularly targeted alpha therapy (TAT) using astatine-211 (211At), a promising alpha-emitting radionuclide for the treatment of resistant cancers. Professor Kabayama has contributed significantly to the design and synthesis of 211At-labeled compounds aimed at first-in-human clinical trials. He has also participated in studies exploring 211At-labeled gold nanoparticles, demonstrating their potent antitumor effects. His work plays a key role in advancing the clinical translation of alpha-based radiopharmaceuticals. In parallel, his research investigates molecular interactions involving lipids and glycans, especially in the context of innate immunity and diseases such as cancer and diabetes. His team develops real-time cellular imaging tools to analyze the dynamics of glycolipids and multivalent glycan-receptor interactions at the membrane level. Through a highly interdisciplinary approach combining organic chemistry, radiobiology, and molecular imaging, Professor Kabayama contributes to the advancement of targeted therapies and the fundamental understanding of complex disease mechanisms. His work positions him at the forefront of innovation in both therapeutic and diagnostic strategies in nuclear medicine.

host : Jean-Pierre POUGET (IRCM)

François LEULIER

Institut de Génomique Fonctionnelle de Lyon (IGFL), UMR 5242 CNRS / E.N.S. de Lyon (France)

"Microbial Influence on Juvenile Physiology"

hôte : Alexandre DJIANE et Jennifer FALCONI (IRCM-Inserm)